EUVIMEDEUVIMED entdecken
Crossref

Abstract FR461: Blood Pressure Responder Analysis in the Global Launch-HTN Trial of Lorundrostat in Uncontrolled and Resistant Hypertension

Manish Saxena, Keith C Ferdinand, Branko Kopjar, Matthew Novin, Debbie L Cohen

Hypertension · 2026-10 · 83 (Suppl_1)

DOI: 10.1161/hyp.83.suppl_1.fr461 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hypertension, 2026-10. Verfasst von Manish Saxena und 4 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction: Hypertension is the most important modifiable risk factor for cardiovascular diseases (CVD), but less than 25% of patients have their blood pressure (BP) under control. The 2025 AHA/ACC Guideline for systolic BP (SBP) targets

Zitieren

APA

Saxena, M., Ferdinand, K. C., Kopjar, B., Novin, M., & Cohen, D. L. (2026). Abstract FR461: Blood Pressure Responder Analysis in the Global Launch-HTN Trial of Lorundrostat in Uncontrolled and Resistant Hypertension. Hypertension, 83(Suppl_1). https://doi.org/10.1161/hyp.83.suppl_1.fr461

Vancouver

Saxena M, Ferdinand KC, Kopjar B, Novin M, Cohen DL. Abstract FR461: Blood Pressure Responder Analysis in the Global Launch-HTN Trial of Lorundrostat in Uncontrolled and Resistant Hypertension. Hypertension. 2026;83(Suppl_1). doi:10.1161/hyp.83.suppl_1.fr461

BibTeX
@article{Saxena2026,
  author = {Saxena, Manish and Ferdinand, Keith C and Kopjar, Branko and Novin, Matthew and Cohen, Debbie L},
  title = {Abstract FR461: Blood Pressure Responder Analysis in the Global Launch-HTN Trial of Lorundrostat in Uncontrolled and Resistant Hypertension},
  journal = {Hypertension},
  year = {2026},
  volume = {83},
  number = {Suppl_1},
  doi = {10.1161/hyp.83.suppl_1.fr461}
}
Kostenlos starten →